Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Current Assets (2020 - 2026)

MoonLake Immunotherapeutics' Current Assets history spans 7 years, with the latest figure at $396.6 million for Q1 2026.

  • Quarterly Current Assets fell 21.65% to $396.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $396.6 million through Mar 2026, down 21.65% year-over-year, with the annual reading at $421.7 million for FY2025, 11.09% down from the prior year.
  • Current Assets came in at $396.6 million for Q1 2026, down from $421.7 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $553.6 million in Q1 2024 to a low of $66.5 million in Q1 2023.
  • The 5-year median for Current Assets is $455.5 million (2025), against an average of $366.8 million.
  • Year-over-year, Current Assets surged 7857.79% in 2022 and then plummeted 42.75% in 2023.
  • MoonLake Immunotherapeutics' Current Assets stood at $76.5 million in 2022, then skyrocketed by 572.01% to $514.2 million in 2023, then decreased by 7.76% to $474.3 million in 2024, then dropped by 11.09% to $421.7 million in 2025, then fell by 5.94% to $396.6 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Current Assets are $396.6 million (Q1 2026), $421.7 million (Q4 2025), and $411.2 million (Q3 2025).